Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
LongGame is a venture capital firm established to fund radical lifespan extension through investments in longevity biotech companies. Founded in the United States, the firm is dedicated to developing technologies that can significantly extend healthy human lifespan. LongGame emphasizes scalable solutions that benefit global populations rather than just the wealthy, aiming to address the root causes of aging through innovative biotech advancements.
The firm operates with a clear mission to invest exclusively in technologies that target a minimum increase of 10 years in healthy lifespan. LongGame's commitment to longevity biotech positions it as a key player in the sector, focusing on advancements that can transform health outcomes for aging populations. The firm is actively involved in the longevity space, seeking to support companies that align with its vision of extending healthy life through scientific breakthroughs.
LongGame's portfolio includes a diverse range of companies working on various aspects of aging and age-related diseases. The firm is based in the United States and is structured to provide strategic guidance and support to its portfolio companies, enhancing their potential for success in the competitive biotech landscape.
LongGame invests exclusively in technologies designed to extend human life beyond current limits, specifically targeting a minimum increase of 10 years in healthy lifespan. The firm emphasizes scalable solutions that benefit global populations rather than just the wealthy. Its investment strategy encompasses advancements in various biotech fields, including artificial intelligence, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, and tissue engineering.
The firm seeks to partner with pre-seed and seed-stage companies that are addressing the root causes of aging through innovative approaches. LongGame prioritizes investments in cellular reprogramming, gene therapy, and age-related disease intervention, focusing on evidence-backed science that can lead to radical lifespan extension. The firm is committed to fostering innovation that promotes healthy lifespan extension and is open to exploring a wide range of biotech solutions that align with its mission.
LongGame's portfolio features a selection of companies that are pioneering advancements in longevity and age-related health. Notable companies include:
These companies represent LongGame's commitment to investing in innovative solutions that address the complexities of aging and promote healthier lifespans.
Will Harborne serves as the General Partner and Chief Investment Officer at LongGame. He is recognized as a longevity investor and has a background in biotech angel investing. His expertise lies in identifying promising technologies that align with LongGame's mission.
Manish Chamoli is the Co-Managing Partner and Chief Scientific Officer. He brings a wealth of knowledge in the biotech field and plays a crucial role in evaluating the scientific merits of potential investments.
Sebastian Brunemeier is also a Co-Managing Partner at LongGame. His experience in the venture capital space contributes to the firm's strategic direction and investment decisions.
Chloe Northcott serves as the Head of Operations, overseeing the firm's operational functions and ensuring that portfolio companies receive the necessary support.
Paolo Binetti acts as an Advisor and Venture Partner, bringing additional expertise from his role at BioTech Ventures at VitaDAO. His insights into the biotech landscape are valuable for LongGame's investment strategy.
To pitch LongGame, founders should visit their website at longgame.vc. The firm has an open pitch policy and accepts applications on a rolling basis. While specific email addresses or application forms are not disclosed, it is recommended that founders include a clear overview of their technology, its potential impact on healthy lifespan extension, and any relevant data supporting their claims in their pitch deck.
LongGame does not specify a formal decision timeline, so founders should be prepared for varying response times. A warm introduction is not required, but it may enhance the chances of engagement.
In recent months, LongGame has made significant strides in the longevity biotech sector. The firm announced investments in several innovative companies, including Deciduous Therapeutics, which focuses on immune-mediated senescent-cell clearance strategies. This investment aligns with LongGame's mission to address the root causes of aging.
Additionally, LongGame continues to expand its portfolio with companies like Cirrus Therapeutics and Repair Biotechnologies, both of which are developing groundbreaking therapies aimed at extending healthy human lifespan. The firm remains active in seeking out new opportunities that align with its investment thesis.
What are LongGame's investment criteria?
LongGame exclusively invests in technologies aimed at extending human life, specifically targeting a minimum increase of 10 years in healthy lifespan. The firm focuses on scalable solutions in various biotech fields, including AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, and tissue engineering.
How can I pitch to LongGame?
Founders can pitch to LongGame through their website at longgame.vc. The firm maintains an open pitch policy and accepts applications on a rolling basis.
What makes LongGame different from other investors?
LongGame is distinct in its exclusive focus on radical lifespan extension technologies. The firm prioritizes investments that address the root causes of aging rather than merely optimizing wellness or managing symptoms.
What is LongGame's geographic focus?
LongGame is based in the United States and primarily invests in companies located within the country, although specific geographic allocations are not disclosed.
What kind of support does LongGame provide to its portfolio companies?
LongGame adds value to its portfolio companies by providing strategic guidance, access to a network of industry experts, and support in navigating the complexities of the longevity biotech landscape.
What is the typical check size for LongGame?
Specific check sizes are not disclosed, but LongGame focuses on pre-seed and seed-stage investments, indicating a willingness to support early-stage companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.